Menu

Pharma News

53 MD002445

Cipla and S&D Pharma make generics deal for Czech Republic and Slovakia

Home/Pharma News | Posted 19/09/2014

India-based generics maker Cipla has partnered with S&D Pharma to launch affordable, high quality generics in the Czech Republic and Slovakia.

Drug shortages 3 V13k14

Patients at risk from UK drug shortages

Home/Pharma News | Posted 12/09/2014

Ongoing drug shortages in the UK have led to 80% of general practitioners (GPs) surveyed reporting that their workloads have increased in the last year. A third of doctors say their patients have been harmed or been negatively affected if a second choice has had to be prescribed.

Teamwork original

Investor principles on biosimilars gained support

Home/Pharma News | Posted 05/09/2014

Amgen and Novartis (parent company of Sandoz, a leader in the biosimilars field) have both come out in support of a set of principles on biosimilars laid down by a coalition of 19 institutional investors.

Label FDA V14b20

Branded drugmaker could be sued for generic’s side effects

Home/Pharma News | Posted 29/08/2014

The Alabama Supreme Court has ruled, for the second time, that Pfizer could be sued for damages allegedly caused by its heartburn drug Reglan (metoclopramide), even if the plaintiff had only taken a generic version of the drug. The ruling follows a rehearing requested by Pfizer, which failed to overturn the original ruling.

Drug Shortages FDA V13K15

Generics shortages continue to rise in the UK

Home/Pharma News | Posted 22/08/2014

There is growing anxiety around the supply of generic medicines in the UK, according to a statement released by the country’s All-Party Pharmacy Group (APPG). The problem is worse than it was two years ago [1], say the cross-bench Members of Parliament who make up the group, and it is not being addressed by the Department of Health’s (DoH) supply chain forum which was set up to address this very issue.

Business Aquisition V13F07

Generics deals for Mylan, Pfizer and Sun Pharma

Home/Pharma News | Posted 14/08/2014

Not to be beaten by biosimilars manufacturers, generics makers are also jumping on the ‘deals’ bandwagon, with a plethora of collaborations announced in the past weeks.

picture 83

Endo to buy generics maker DAVA

Home/Pharma News | Posted 01/08/2014

Specialty pharmaceuticals maker Endo Health Solutions (Endo) announced on 24 June 2014 that it had reached a definitive agreement to acquire generics maker DAVA Pharmaceuticals for US$575 million in cash, with another US$25 million up for grabs depending on the achievement of certain sales milestones.

Shaking hands V13D29

Abbott to buy Russian generics firm

Home/Pharma News | Posted 04/07/2014

US-based pharma company Abbott Laboratories (Abbott) announced on 23 June 2014 that it had signed a definitive agreement to acquire Russian generics maker Veropharm.

DNA Kaku V13C15

Pfenex looking for funding for its biosimilars pipeline

Home/Pharma News | Posted 27/06/2014

US biotechnology firm Pfenex is looking to raise more than US$45 million to further its biosimilars pipeline.

Teamwork check mark V13D12

Views on biosimilars at Amgen and Actavis

Home/Pharma News | Posted 20/06/2014

Biotech giant Amgen and US generics maker Actavis entered into a collaboration for the development and commercialization of several cancer antibody biosimilars back in December 2011 [1]. Now the two companies have spoken to GaBI about their views on biosimilars and their biosimilar plans [2].

Harmonize V13F28

Top 10 most read GaBI Online articles in 2013

Home/Pharma News | Posted 07/02/2014

2013 was a busy year with lots of developments in the biosimilars arena, ranging from revision of regulatory guidelines to new biosimilar approvals. Biosimilars remain the hot topic of the year for GaBI Online during 2013 and in fact all 10 of the most read articles concern biosimilars.

Latin America V13J25

Abbott expands generics business in Latin America

Home/Pharma News | Posted 06/06/2014

US-based pharma company Abbott Laboratories (Abbott) announced on 16 May 2014 that it was expanding its presence in Latin American and increasing its branded generics portfolio with the acquisition of CFR Pharmaceuticals (CFR).

picture45

Pamplona investment group buys majority share in Alvolgen

Home/Pharma News | Posted 16/05/2014

Specialist investment manager Pamplona Capital Management (Pamplona) announced on 2 April 2014 that it had acquired a majority stake in US generics company Alvogen, one of the fastest growing generics companies in the pharmaceutical industry.

Business Aquisition V13F07

Actavis to acquire generics from Akorn

Home/Pharma News | Posted 02/05/2014

US generics major Actavis announced on 17 April 2014 that it had made a deal with Akorn and Hi-Tech Pharmacal (Hi-Tech) to buy five of their products.

Patent 2 V13E31

UK court invalidates Herceptin patents

Home/Pharma News | Posted 25/04/2014

A High Court in the UK has overturned two key patents on Roche’s breast cancer blockbuster Herceptin (trastuzumab).

Shaking hands V13D29

Sun Pharma to acquire Ranbaxy creating 5th largest generics firm

Home/Pharma News | Posted 18/04/2014

India-based Sun Pharmaceutical (Sun Pharma) announced on 6 April 2014 that the company had agreed to acquire rival generics maker Ranbaxy Laboratories (Ranbaxy) in an all-stock deal worth US$3.2 billion.

picture50

Actavis buys Thai generics company

Home/Pharma News | Posted 11/04/2014

US generics major Actavis has acquired Silom Medical Company, a privately held generics firm focused on developing and marketing therapies in Thailand, for around US$100 million in cash.

Pay for Delay DrugsMoneyGeneric V13F21

US FTC hopes to collect US$1 billion from pay-for-delay settlement

Home/Pharma News | Posted 04/04/2014

The US Federal Trade Commission (FTC) is looking to collect more than US$1 billion from a settlement with pharmaceutical companies it has sued for their part in what the FTC terms ‘pay-for-delay’ deals.

Australia flag V13C29

Anticompetitive practices come under scrutiny in Australia

Home/Pharma News | Posted 28/03/2014

The Australian Competition and Consumer Commission (ACCC) has started proceedings in the Federal Court against Pfizer Australia (Pfizer) alleging that offers made by Pfizer to pharmacies before the expiry of the patents for its blockbuster cholesterol-lowering drug Liptor (atorvastatin) were anticompetitive.

Teamwork original

Actavis to acquire specialty drugmaker Forest Labs

Home/Pharma News | Posted 07/03/2014

US-based generic drugmaker Actavis is set to grow even bigger, with the acquisition of US-based Forest Laboratories (Forest Labs), according to an announcement by the companies on 18 February 2014.